 AIM ImmunoTech Inc. provided a status update on its Phase 2a Human Challenge Trial HCT to test the companys flagship drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus HRV-16, which is a common cold virus, and influenza A virus H3N2. 